DIR-214 Trial of a genetically modified (GM) vaccine for the prevention of respiratory disease in horses

Between 17 March to 28 April we sought your feedback on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) prepared for DIR-214 licence application (Trial of a genetically modified (GM) vaccine for the prevention of respiratory disease in horses). 

During the 6-week consultation period we received email advice from prescribed Government agencies and the Gene Technology Technical Advisory Committee but did not receive any public feedback.

We heard support for:

• the thoroughness of the RARMP
• the proposed limits and controls listed in the RARMP
• the overall conclusions of the RARMP

We analysed the feedback provided during the public consultation process and took into account submitter suggestions to improve clarity on the methods of decontamination and the origin of the genetic material inserted into the GMO in finalising the RARMP (comments addressed in Appendix A).

The Gene Technology Regulator issued a licence to The University of Queensland for their research work with the GM vaccine for horses on 4 June 2025. More details are available at DIR 214 | Office of the Gene Technology Regulator.

We appreciate all those who provided input to the consultation – your feedback will help to ensure the OGTR continues to manage any risks posed by gene technologies to people and the environment.